Superworth

Puma Biotechnology PE ratio PBYI

Share price divided by earnings per share over the last twelve months, since 2022.

Today, Nov 2, 2026
19.6×
4-year median
12.3×
Against its 4-year history
76th
percentile: 0 is its lowest day, 100 its highest
4-year range
3.8× to 88.9×
Peer median
11.3×

Puma Biotechnology's PE ratio is 19.6× as of Nov 2, 2026: a share price of $10.18 against $0.52 of earnings per share over the last twelve months.

That is above its 4-year median of 12.3×, higher than on 76% of days in the last 4 years.

Over that time it ranged from 3.8× in Aug 2025 to 88.9× in Feb 2024.

The median for 10 large drugmakers of a similar size is 11.3×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far19.6×7.8×21.2×
20258.3×3.8×8.3×
20246.4×5.0×88.9×
202354.1×18.0×54.3×
202219.2×12.3×22.3×

Against its peers

Companies in Drug Manufacturers - General nearest Puma Biotechnology's size, closest first, today.

Where Puma Biotechnology ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Puma Biotechnology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.